KRONOS BIO INC (KRON) Stock Price, Quote, News and Overview
NASDAQ:KRON - Nasdaq - US50107A1043 - Common Stock - Currency: USD
KRON Quote, Performance and Key Statistics
0.88
+0.01 (+0.89%)
The current stock price of KRON is 0.88 USD. In the past month the price increased by 21.38%. In the past year, price decreased by -18.52%.
KRON Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.74 | 339.89B | ||
| AMGN | AMGEN INC | 14.32 | 159.86B | ||
| GILD | GILEAD SCIENCES INC | 14.48 | 139.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.78 | 56.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.73B | ||
| ARGX | ARGENX SE - ADR | 102.05 | 35.83B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.08 | 29.91B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.22B | ||
| NTRA | NATERA INC | N/A | 22.44B | ||
| BIIB | BIOGEN INC | 8.36 | 19.39B | ||
| INSM | INSMED INC | N/A | 17.65B |
Related stock screener links
About KRON
Company Profile
Kronos Bio, Inc. is a clinical development biopharmaceutical company. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. The company is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. The company has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. The company is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.
Company Info
KRONOS BIO INC
1300 S. El Camino Real, Suite 400
San Mateo CALIFORNIA 94402 US
CEO: Norbert Bischofberger
Employees: 10
Phone: 16507815200
KRONOS BIO INC / KRON FAQ
What is the stock price of KRONOS BIO INC today?
The current stock price of KRON is 0.88 USD. The price increased by 0.89% in the last trading session.
What is the ticker symbol for KRONOS BIO INC stock?
The exchange symbol of KRONOS BIO INC is KRON and it is listed on the Nasdaq exchange.
On which exchange is KRON stock listed?
KRON stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KRONOS BIO INC stock?
7 analysts have analysed KRON and the average price target is 2.3 USD. This implies a price increase of 160.8% is expected in the next year compared to the current price of 0.88. Check the KRONOS BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KRONOS BIO INC worth?
KRONOS BIO INC (KRON) has a market capitalization of 53.65M USD. This makes KRON a Micro Cap stock.
How many employees does KRONOS BIO INC have?
KRONOS BIO INC (KRON) currently has 10 employees.
What are the support and resistance levels for KRONOS BIO INC (KRON) stock?
KRONOS BIO INC (KRON) has a resistance level at 0.89. Check the full technical report for a detailed analysis of KRON support and resistance levels.
Is KRONOS BIO INC (KRON) expected to grow?
The Revenue of KRONOS BIO INC (KRON) is expected to decline by -100% in the next year. Check the estimates tab for more information on the KRON EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KRONOS BIO INC (KRON) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KRON, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KRON, evaluating the profitability, health, valuation and growth aspects
- KRONOS BIO INC (KRON) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KRONOS BIO INC (KRON) Sales and EPS estimates to see what analysts future expectations are.
- KRONOS BIO INC (KRON) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KRONOS BIO INC (KRON) Insider and Institutional Ownership to learn about the owners and their transactions.
- KRONOS BIO INC (KRON) Stock Chart to make your own analysis
- KRONOS BIO INC (KRON) Latest news and press-releases to stay up to date.
Does KRONOS BIO INC (KRON) stock pay dividends?
KRON does not pay a dividend.
When does KRONOS BIO INC (KRON) report earnings?
KRONOS BIO INC (KRON) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of KRONOS BIO INC (KRON)?
KRONOS BIO INC (KRON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.07).
What is the Short Interest ratio of KRONOS BIO INC (KRON) stock?
The outstanding short interest for KRONOS BIO INC (KRON) is 1.22% of its float. Check the ownership tab for more information on the KRON short interest.
KRON Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to KRON. When comparing the yearly performance of all stocks, KRON is a bad performer in the overall market: 81.08% of all stocks are doing better.
KRON Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KRON. KRON has a great financial health rating, but its profitability evaluates not so good.
KRON Financial Highlights
Over the last trailing twelve months KRON reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS increased by 46.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -59.63% | ||
| ROE | -80.8% | ||
| Debt/Equity | 0 |
KRON Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to KRON. The Buy consensus is the average rating of analysts ratings from 7 analysts.